Bayesian Capital Management LP Acquires New Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Bayesian Capital Management LP bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 21,600 shares of the biopharmaceutical company's stock, valued at approximately $1,995,000.

Several other large investors have also modified their holdings of the business. Bellevue Group AG increased its position in shares of Gilead Sciences by 5.2% during the fourth quarter. Bellevue Group AG now owns 48,429 shares of the biopharmaceutical company's stock valued at $4,473,000 after acquiring an additional 2,402 shares during the last quarter. Bearing Point Capital LLC purchased a new stake in Gilead Sciences in the fourth quarter valued at approximately $588,000. BLI Banque de Luxembourg Investments acquired a new position in Gilead Sciences during the fourth quarter worth $2,302,000. Algert Global LLC acquired a new position in Gilead Sciences during the 4th quarter worth about $3,214,000. Finally, Alteri Wealth LLC acquired a new position in Gilead Sciences in the 4th quarter valued at about $306,000. Institutional investors and hedge funds own 83.67% of the company's stock.

Gilead Sciences Stock Performance

Shares of GILD traded down $1.30 during mid-day trading on Friday, reaching $96.86. 13,012,961 shares of the company's stock were exchanged, compared to its average volume of 7,593,595. The business's fifty day simple moving average is $107.59 and its 200-day simple moving average is $99.17. Gilead Sciences, Inc. has a 52-week low of $62.07 and a 52-week high of $119.96. The stock has a market capitalization of $120.61 billion, a PE ratio of 261.78, a price-to-earnings-growth ratio of 0.71 and a beta of 0.26. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, beating analysts' consensus estimates of $1.77 by $0.04. The business had revenue of $6.67 billion during the quarter, compared to analysts' expectations of $6.77 billion. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The business's revenue was down .3% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.32) earnings per share. On average, equities research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be issued a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a dividend yield of 3.26%. The ex-dividend date of this dividend is Friday, June 13th. Gilead Sciences's payout ratio is currently 66.53%.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $104.09, for a total value of $260,225.00. Following the sale, the chief financial officer now owns 169,061 shares of the company's stock, valued at approximately $17,597,559.49. The trade was a 1.46 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold 160,605 shares of company stock worth $16,718,136 over the last 90 days. 0.27% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several research analysts have recently commented on GILD shares. The Goldman Sachs Group raised their price objective on shares of Gilead Sciences from $85.00 to $96.00 and gave the company a "neutral" rating in a research note on Wednesday, February 12th. Cantor Fitzgerald began coverage on Gilead Sciences in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 target price for the company. Royal Bank of Canada upped their price target on Gilead Sciences from $84.00 to $90.00 and gave the stock a "sector perform" rating in a report on Wednesday, February 12th. JPMorgan Chase & Co. lifted their price objective on Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a research note on Thursday, March 27th. Finally, DZ Bank upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 target price on the stock in a research note on Thursday, February 13th. Nine research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $110.55.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.